Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business highlights for the three and nine months ended September 30, 2022.

Mydecine held cash and cash equivalents for a total of $88,933, compared to a total of $1,495,311 on December 31, 2021.

R&D expenses for the three and nine months ended September 30, 2022, were $467,169 and $2,169,180, respectively, as compared to $560,231 and $1,882,361 in the same time periods ended September 30, 2021.

Net loss attributable to common stockholders was $11.47 million from operations (or a basic and diluted loss per share of $1.57), compared to $18.02 million (or a basic and diluted loss per share …

Full story available on Benzinga.com